Assessing the role of statin therapy in bladder cancer: evidence from a Mendelian Randomization study

• Published in: Frontiers in pharmacology Vol. 15; p. 1427318
• Main Authors: Li, Rongkang, Huang, Guixiao, Li, Yunfei, Huang, Mou, Huang, Ying, Li, Yingrui, Li, Guangzhi, Wu, Song
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 19.07.2024
• Subjects: bladder cancer; causal analysis; GWAS; Mendelian Randomization; statin; causal analysis; Mendelian Randomization; GWAS; statin; bladder cancer
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2024.1427318

Statins, which are medications that lower lipid levels, are extensively used to decrease cardiovascular disease risk. Recently, the use of statins in cancer prevention has attracted considerable interest. However, it is still unclear whether the use of statins has a causal effect on bladder cancer. The two-sample Mendelian Randomization (MR) was performed to infer the causal relationship between statin therapy (atorvastatin, simvastatin, and rosuvastatin) and bladder cancer. Single-nucleotide polymorphisms (SNP)-based genome-wide association studies (GWAS) of statins (atorvastatin, simvastatin, and rosuvastatin) were gathered from the UK Biobank, involving 462,933 participants. We acquired summary-level genetic data on bladder cancer from a European cohort of 175,121 individuals. The inverse variance weighted (IVW) method was the main analytical technique used, supplemented by MR-Egger, weighted median, weighted mode, and simple mode to estimate causal effects. Additionally, sensitivity analyses were conducted to verify the robustness and reliability of our findings. Based on the IVW analysis, we identified a significant causal association between rosuvastatin use and a decreased risk of bladder cancer, with genetic analysis inferring the substantial reduction in odds (OR = 3.52E-19, 95% CI: 5.48E-32-2.26E-06, = 0.005). In contrast, the IVW results did not reveal a statistically significant relationship between the genetically estimated use of atorvastatin (OR = 7.42E-03, 95% CI: 6.80E-06-8.084, = 0.169) or simvastatin (OR = 0.135, 95% CI: 0.008-2.330, = 0.168) and bladder cancer risk. We investigated the causal link between statin therapy (atorvastatin, simvastatin, and rosuvastatin) and bladder cancer using a two-sample Mendelian Randomization analysis among the European population. Our findings indicated that genetically predicted use of rosuvastatin was associated with a decreased risk of bladder cancer, whereas no significant genetically predicted causal effects were observed for atorvastatin and simvastatin use.